Anti-inflammatory agents

Details Anti-inflammatory agents Anti-inflammatory agents

2005-04-12

2005-04-12

O'Sullivan, Peter (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S247000, C544S008000, C544S239000

Reexamination Certificate

active

06878702

ABSTRACT:
The use of mitochondrial KATPchannel openers, particularly compounds of general formula (I), for the treatment or prevention of inflammation by inducing apoptosis of inflammatory cells.

REFERENCES:
patent: 5185332 (1993-02-01), Haikala et al.
patent: 0 383 449 (1990-08-01), None
patent: 0 565 546 (1993-10-01), None
patent: WO 9953024 (1999-10-01), None
Jouko Levijoki et al., “Further Evidence for the Cardiac Troponin C Mediated Calcium Sensitization by Levosimendan: Structure-response and Binding Analysis with Analogs of Levosimendan”, J. Mol. Cell Cardiol, vol. 32, Mar. 1, 2000, pp. 479-491.
Elaine J. Tanhehco, “Potassium channel modulators as anti-inflammatory agents”, Expert Opin. Ther. Patents, vol. 11, no. 7, Jul. 2001, pp. 1137-1140.
Dalia M. Kopustinskiene et al., “Levosimendan is a mitochondrial KATPchannel opener”, European Journal of Pharmacology, vol. 428, No. 3, 2001, pp. 311-314.
Andre Terzic et al., “Mitochondrial KATPChannel: Probing Molecular Identity and Pharmacology”, J. Mol. Cell Cardiol, vol. 32, no. 11, Nov. 2000, pp. 1911-1915.
K. H. Buchheit et al., “KATPChannel Openers for the Treatment of Airways Hyperractivity”, Pulmonary Pharmacology & Therapeutics, vol. 12, 1999, pp. 103-105.
Abstract of S. Antila et al., “Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol”, Arzneim. Forsch.(47, No. 7), 1997, pp. 816-820.
Abstract of L. Lehtonen et al., “Safety on Levosimendan and other calcium sensitizers”, J. Cardiovasc. Pharmacol. (26, Suppl. 1), 1995, pp. 70-76.
Abstract of A. Szewczyk et al., “Mitochondria: a new target for K+ channel openers!”, document No. 131:208351, Trends Pharmacol Sci, vol. 20, no. 4, 1999, pp. 157-161.
Abstract of M. Luotolahti et al., “Levosimendan, a calcium sensitizer and potassium channel opener, is safe and improves left ventricular function in acute myocardial infarction” document No. PREV199900514091 Circulation, vol. 98, no. 17, Oct. 27, 1998, pp. l105-l106.

Affiliated with

Also associated with

Rating

Anti-inflammatory agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-inflammatory agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3440972